• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:DK200700025U1
    申请号:DK200700025U
    申请日:2007-01-25
    公开日:2007-06-08
    发明作者:Bastarda Andrej；Salobir Mateja；Grahek Rok
    申请人:Lek Pharmaceuticals；
    IPC主号:
    专利说明:

    DK 2007 00025 U4
    Stabilized pharmaceutical preparation containing amorphous atorvastatin calcium
    The present invention relates to the field of pharmaceutical technology and relates to packages of pharmaceutical compositions containing amorphous atorvastatin calcium, preferably useful for the treatment of hypercholesterolemia and hyperlipidemia. The preparation enables the preparation of a stable pharmaceutical composition containing amorphous atorvastatin calcium, which is known to be unstable in an acidic environment and sensitive to heat, light, moisture and low pH, in a technically simple manner.
    Atorvastatin calcium ((R- (R *, R *)) - 2 (4-fluorophenyl) -β, 6-dihydroxy-5- (1-methylethyl) -3-phenyl-4 ((phenylamino) carbonyl) - 1H-pyrrole-1-heptanoic acid hemicalcium salt) is useful as an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), an enzyme associated with the intracellular cholesterol synthesis, HMG-CoA reductase enzyme inhibitors. are therefore considered particularly useful in the treatment of hypercholesterolemia and hyperlipidemia.
    The processes for producing atorvastatin calcium and its key intermediates are described in U.S. Patent Nos. 5,003,080, 5,097,045, 5,103,024, 5,124,482, 5,149,837, 5,155,251, 5,216,174, 5,245,047, 5,248,793. , 5,280,126, 5,342,952, and 5,397,792.
    Atorvastatin calcium may be present in an amorphous form or in various crystalline forms described in patent applications WO 97/3958, WO 97/3959, WO 01/36384, WO 02/41834, WO 02/43732, WO 02/51804 and WO 02/57229. The processes for preparing amorphous atorvastatin calcium are described in patent applications WO 97/3960, WO 00/71116, WO 01/28999, WO 01/42209, WO 02/57228 and WO 02/59087.
    It is well known that active compounds in an amorphous form are more soluble and dissolve faster than in a crystalline form. The advantage of an amorphous active compound over a crystalline form is particularly evident in cases of less soluble compounds, such as atorvastatin calcium, which have a better bioavailability of the active compound.
    It is known from the patent literature and the relevant literature that atorvastatin calcium is an unstable compound which is sensitive to heat, moisture, light and low pH where atorvastatin calcium is converted from the carboxylic acid form to the lactone form (US 5,686,101; 2 DK 2007 00025 U4
    Hurley, T.R. et al. Tetrahedron (1993), 49, 1979-1984). The problem of instability of atorvastatin calcium has so far been solved with the addition of excipients to a pharmaceutical composition for stabilizing atorvastatin calcium, especially in view of the conversion to the lactone form, by the addition of a basic agent or a buffering agent to a pharmaceutical composition (WO 00 / 35425 and WO 94/16603). An stabilization of an active compound is known in which an alkaline compound or buffer solution is added to form an alkaline stabilized compound in the final synthesis phase as described in patent application WO 01/93860. WO01 / 93859 discloses a formulation comprising amorphous atorvastatin and a substance capable of binding and / or neutralizing carbon dioxide. The present invention is based on an alternative way of obtaining a stable formulation by enclosing the formulation with an inert gas and using gas impervious packing materials.
    The use of a pharmaceutical composition containing amorphous atorvastatin calcium as the active compound is advantageous over a pharmaceutical composition containing a crystalline compound because the amorphous compound dissolves faster and better, which is an important factor in the bioavailability of the active compound in the body. It is well known that the stability of an active compound depends on a polymorphic form in which it occurs and that an amorphous form is less stable than a crystalline form, showing that an amorphous form is even more sensitive to heat, light, moisture and low pH than a crystalline form. All of these factors are of particular importance for the stability of a pharmaceutical composition containing an amorphous compound. Impurities formed by the decomposition of an active compound lower the therapeutic effect of an active compound and also unnecessarily burden the body with unnecessary decomposition products. An appropriate and useful pharmaceutical composition containing amorphous atorvastatin calcium has not been described to date.
    Therefore, there is a continuing need for a stable pharmaceutical composition containing amorphous atorvastatin calcium. The present invention ensures an increased bioavailability by including the amorphous form of atorvastatin calcium enclosed by an inert gas which stabilizes the composition by preventing degradation of the carboxylic acid form of atorvastatin to the lactone form. The stability of the composition is ensured by packing the formulation and the surrounding inert gas into gas-impermeable materials. This is a simple and economically beneficial way to prepare a stable bioavailability preparation for the treatment of hypercholesterolemia and hyperlipidemia.
    3 3DK 2007 00025 U4
    Surprisingly, we have found that the stability of amorphous atorvastatin calcium is affected by the oxygen content of an environment. There is a linear dependence between the amount of decomposition products and the oxygen content of the atmosphere. If half of the oxygen content of an atmosphere is replaced by an inert gas under defined temperature conditions, the formation of the degradation products is halved over a fixed period of time. If amorphous atorvastatin calcium is stored at a defined temperature in an atmosphere with a minimum oxygen content, the amount of degradation products after a certain period of time will be less than and / or equal to that when crystalline atorvastatin calcium is stored in air.
    By analyzing the amount of degradation products in the pharmaceutical composition containing amorphous atorvastatin calcium, we have found that the amount of degradation products in the amorphous compound increases significantly when stored in air. Surprisingly, we have found that the stability of the pharmaceutical composition is significantly improved if the pharmaceutical composition is stored in an atmosphere of minimal oxygen content. If a pharmaceutical composition containing amorphous atorvastatin calcium is stored at a defined temperature in an atmosphere with a minimum oxygen content, the amount of degradation products over a certain period of time is less than and / or equivalent to that of a pharmaceutical composition containing crystalline atorvastatin calcium stored in air. .
    The preparation comprises a package containing a pharmaceutically stable composition with amorphous atorvastatin calcium enclosed by an inert gas atmosphere. A stabilized pharmaceutical composition of the present invention, containing amorphous atorvastatin calcium, does not burden the body with additional compounds. A further advantage of stabilizing the pharmaceutical product of the present invention is that the obtained stability of the pharmaceutical composition is better than that containing crystalline atorvastatin calcium.
    The pharmaceutical composition may be of any form, such as tablets, orally dispersible pharmaceutical preparations, capsules, pills, granules, etc., suitable for storage in a gas-impervious package. Nitrogen or argon may preferably be used as an inert gas atmosphere, with nitrogen being particularly preferred.
    4 DK 2007 00025 U4
    The packing material is preferably selected from the group consisting of an AI / AI blister pack, an AI polychloro-3-fluoroethylene homopolymer / PVC laminate blister pack or a bottle.
    The stable pharmaceutical product of the present invention can be used in the treatment of hypercholesterolemia and hyperlipidemia.
    Another object of the present invention is a package containing a stable pharmaceutical composition containing amorphous atorvastatin calcium as an active compound and pharmaceutically acceptable excipients. The goal is achieved by storing the pharmaceutical composition in an inert atmosphere, thereby achieving the stability which is better than and / or corresponding to the stability of the pharmaceutical composition containing the crystalline active compound. Improving the stability of the pharmaceutical composition comprising amorphous atorvastatin calcium by storing the pharmaceutical composition in an inert atmosphere is advantageous over known stability improvements of the amorphous active compound because it is technologically simple and not economically demanding. Moreover, the pharmaceutical composition does not burden the body with additional compounds. The term "inert atmosphere" means an atmosphere with a minimum oxygen content.
    The pharmaceutical composition of the present invention can be in any form used in the pharmaceutical industry, such as tablets, orally dispersible preparations, capsules, pills, granules, etc. Nitrogen or argon can be used on the inert gas to preserve an inert atmosphere , where nitrogen is particularly preferred. The pharmaceutical composition may be stored in an inert atmosphere in AI / AI blister pack, Al polychloro-3-fluoroethylene homopolymer / PVC laminate blister pack, bottles or gas impervious plastic bag.
    The present invention is illustrated but in no way limited by the following examples:
    Example 1
    Samples, each containing 100 mg of crystalline and amorphous atorvastatin calcium, were transferred to 10 ml vials closed with a rubber stopper in an atmosphere of different oxygen content relative to the air composition. Nitrogen with 99% (v / v) purity was used as an inert gas. The samples were stored at 80 ° C for 6 days and the amount of impurities was then determined by high performance liquid chromatography (HPLC). The oxygen content of the vials was determined by gas chromatography with a mass spectrometric detector (GC / MS).
    The decomposition products were determined by gas chromatography Agilent Technologies (Waldbronn, Germany) model HP 1100. Chromatograms were recorded with a UV detector at 250 nm. The column Chromolite Performance RP-18e 100 x 4.6 mm (Merck, Darmstadt, Germany) and the gradient for mobile phase A: 20 mM ammonium acetate pH 4.5, 5% (v / v) tetrahydrofuran and 25% (v / v) vol.) acetonitrile and the gradient of mobile phase B: 20 mM ammonium acetate pH 4.0, 5% (v / v) tetrahydrofuran and 70% (v / v) acetonitrile were used. The composition of the mobile phase was set such that first and until 2 minutes there was 25% of mobile phase B (75% mobile phase A), from 2 minutes to 4.7 minutes the composition of the mobile phase changed linearly to 100% of mobile phase B, and it remained that way until the end of the assay at 5.5 minutes. The flow rate for the mobile phase was 7 ml / minute. Under the above conditions, the retention time of atorvastatin calcium is approx. 1.4 minutes. The atorvastatin calcium samples were dissolved in the solvent 200 mM Tris pH 7, 40% (v / v) acetonitrile at a concentration of 0.5 mg / ml.
    Analytical method for determining the amount of oxygen in the vials and blisters:
    The analyzes were performed on a gas chromatograph Varian (Walnut Creek, USA model Varian 3400 and mass detector Finnigan (San José, USA) model SSQ700. The capillary column PLOT Coating Mosieve 5A 25 m long with an inner diameter of 0.32 mm (Variana) was used. The temperature of the column was 50 ° C, the temperature of the injector was 150DC, and the temperature of the assembly with the mass detector was 150 ° C. The flow rate through the column was 2 ml of helium per minute The injection mode was divided by the 1; 100 ratio. with electrons at 70 eV in the mass range from 20 to 60 mass units for 0.3 seconds.
    Hood bottles and blister packs were placed in a chamber with an argon atmosphere. 50 µl gas samples were taken with gas injection and immediately analyzed. The argon atmosphere prevented contamination of the samples with oxygen during sampling.
    6 DK 2007 00025 U4
    The signal for the molecular oxygen ion 32 m / z with a retention of approx. 1.9 minutes and the signal for the molecular nitrogen ion 28 m / z with a retention of approx. 3.1 minutes were detected with the gas detector. The oxygen content was accordingly calculated in relation to the sum of oxygen and nitrogen.
    Oxygen content in atmosphere in% Crystalline atorvastatin caldum Increase in the amount of degradation products in% relative to active starting compound Amorphous atorvastatin calcium Increase in degradation product in% compared to active starting compound 0.6 0 0 2.8 0 0.13 12 , 2 0.02 0.49 21.3 0.05 0.89
    Table 1: Increase in the amount of degradation products in the compounds stored under stress conditions (6 days at a temperature of 80 ° C) for comparison with the active starting compound.
    The experimental results for the amount of degradation products in crystalline and amorphous atorvastatin calcium at different oxygen contents in the atmosphere have shown that at a minimum oxygen content, the amount of degradation products is similar in both active compounds, showing that the stability of amorphous atorvastatin calcium is stored in an inert atmosphere. corresponds to the stability of crystalline atone / astatin calcium. The measurements also show that the process of storing amorphous atorvastatin calcium in an inert atmosphere improves the stability of the amorphous compound, but has no effect on the stability of crystalline atorvastatin calcium.
    Example 2
    Tablets containing 10 mg of amorphous atorvastatin calcium not previously stabilized by storage in an inert atmosphere, and other pharmaceutically acceptable excipients (microcrystalline cellulose, I actosemon ohydrate, cross-linked carboxylmethylcellulose, polysorbate 80, hydroxypropylcellulose i of glass closed with rubber stoppers in normal atmosphere (air) and atmospheres of different oxygen content which were replaced by inert gas. Nitrogen with 99% purity (v / v) was used as an inert gas, and tablets containing 10 mg of crystalline atorvastatin calcium stored in 10 ml vials closed with rubber stoppers in normal atmosphere (air) were used for 7 DK 2007 00025 U4 comparison. Each vial contained one tablet. These vials were placed in a dryer for 6 days under stress conditions at 80 ° C.
    The samples for analyzing the amount of degradation products were prepared by adding 10 ml of a solvent to the tablet in a suitable container and the tablet was dissolved by ultrasound in an ultrasonic bath for 10 minutes. The tablet was dissolved and the resulting suspension was filtered through the 0.45 µm PTFE injection filter. The clear solution was analyzed by the procedure described in Example 1.
    Tablet stored in an atmosphere with oxygen content in% Increase in the amount of degradation products in% compared to active starting compound 21.0 3.11 12.4 0.94 0.4 0.01
    Table 2: Increase in the amount of degradation products compared to the active starting compound - amorphous atorvastatin calcium in the tablets stored under the stress conditions (6 days at 80 ° C).
    Tablet stored in an atmosphere with oxygen content in% Increase in the amount of degradation products in% compared to active starting compound 21.2 0.30
    Table 3: Increase in the amount of degradation products compared to the active starting compound - crystalline atorvastatin calcium in the tablets stored under the stress conditions (6 days at 80 ° C).
    The experimental results for the amount of degradation products in the pharmaceutical composition containing amorphous atorvastatin calcium stored in atmospheres with different oxygen contents have shown that the increase in the amount of degradation products is within the measurement error of the minimum oxygen content in an atmosphere. The stability of the pharmaceutical composition containing amorphous atorvastatin calcium stored in an inert atmosphere is better than the stability of a pharmaceutical composition containing crystalline atorvastatin calcium stored in a normal atmosphere. On the other hand, the stability of the active compound is significantly lower because there is only a 3% increase in the amount of degradation products compared to the starting value of the amorphous atorvastatin calcium containing the pharmaceutical composition containing amorphous atorvastatin. calcium is stored in a normal atmosphere. Interestingly, after replacing half of the oxygen with an inert gas, the increase decreases by two-thirds to the values when a pharmaceutical composition is stored in air.
    Example 3
    Tablets containing 20 mg of amorphous atorvastatin calcium not previously stabilized by storage in an inert atmosphere, and other pharmaceutically acceptable excipients (microcrystalline cellulose, lactose monohydrate, cross-linked carboxymethyl cellulose, polysorbate 80, hydroxypropyl cellulose packed in magnesium blacks) on an industrial blister packing machine. The first tablet portion was packed in normal atmosphere (air). The second batch, before the top foil seal, was packed in an atmosphere of technical argon 99% (v / v). In comparison, the tablets containing 10 mg of crystalline atorvastatin calcium were stored in normal atmosphere in 10 ml vials. The oxygen content of the blister pack in argon atmosphere was determined by gas chromatography with a mass spectrometric detector (GC / MS).
    The stress test to store the blister packs under stress conditions (6 days at 80 ° C) was performed. In comparison, the tablets containing 10 mg of crystalline atorvastatin calcium in blister packs with a normal atmosphere (air) were used and they were exposed to the stress conditions. The difference in the amount of impurities for atorvastatin in the blister packs was determined by the procedure described in Example 2.
    Amorphous Compound Crystalline Compound Sample Oxygen content in% in atmosphere Increase in amount of degradation products in% in prefabrication to active starting compound Increase in amount of degradation products in% in prefabrication to active starting compound Normal atmosphere (air) Tablet 1 21.0 0.91 0.13 Tablet 2 21.0 0.87 0.15 Tablet 3 21.0 0.95 0.12 Inert gas atmosphere Tablet 1 2.4 0.01 Tablet 2 2.3 0.02 Tablet 3 2.1 0.03 9 DK 2007 00025 U4
    Table 4: Increase in the amount of degradation products compared to the active starting compound - amorphous / crystalline atorvastatin calcium in the tablets depending on the oxygen content of the atmosphere at packaging.
    The test results for the amount of degradation products in the pharmaceutical composition containing amorphous atorvastatin calcium, when the pharmaceuticals were packed in the blisters in an inert gas atmosphere, show that an increase in the amount of degradation products under stress conditions is within the amorphous active compound, suggest that the amorphous compound, pharmaceutical formulation or pharmaceutical composition containing the amorphous compound is stable during prolonged storage if an inert gas atmosphere is used during packing in blister packs. Surprisingly, the results show the fact that the method of stabilizing the pharmaceutical composition containing amorphous atorvastatin calcium, and comprising packing the pharmaceutical composition in a blister pack in an inert gas atmosphere, provides better results for the stability than the pharmaceutical composition containing crystalline atorvastatin. calcium packed in air.
    权利要求:
    Claims (10)
    [1]
    A package containing a pharmaceutical formulation with amorphous atorvastatin calcium enclosed by an inert gas atmosphere.
    [2]
    A gasket according to claim 1, wherein the formulation is packed in a gas impermeable material which is substantially impermeable.
    [3]
    A package according to claim 2, wherein the packaging material is selected from the group consisting of an AI / AI blister pack, an AI polychloro-3-fluoroethylene homopolymer / PVC laminate blister pack or a bottle.
    [4]
    A gasket according to any preceding claim, wherein the inert gas is nitrogen or argon.
    [5]
    A package according to any one of the preceding claims, wherein the pharmaceutical formulation is in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pills or granules.
    [6]
    A package containing a pharmaceutical formulation with amorphous atorvastatin calcium and pharmaceutically acceptable excipients enclosed by an inert gas atmosphere.
    [7]
    The gasket of claim 6, wherein the formulation is in a gas exchange material which is substantially impermeable.
    [8]
    The gasket of claim 7, wherein the gas-impermeable gasket material is selected from the group consisting of an AI / AI blister pack, an Al polychloro-3-fluoroethylene homopolymer / PVC laminate blister pack or a bottle.
    [9]
    The gasket of claims 6 to 8, wherein the inert gas is nitrogen or argon.
    [10]
    A package according to claims 6 to 9, wherein the pharmaceutical composition is in the form of tablets, orally dispersible pharmaceutical formulations, capsules, pills or granules.
    类似技术:
    公开号 | 公开日 | 专利标题
    DK200700025U4|2008-03-14|Stabilized pharmaceutical composition containing an amorphous active compound
    EP1795197B1|2013-01-23|Pharmaceutical compositions comprising an antibiotic
    EP1653930B1|2007-12-19|Methods for the stabilization of atorvastatin
    US20100179184A1|2010-07-15|Article of manufacture for prasugrel
    EA017885B1|2013-03-29|HYDROGENSULFATE SALT OF 2-ACETOXY-5-|-4,5,6,7-TETRAHYDROTHIENO[3,2-c]PYRIDINE AND ITS PREPARATION
    KR20070106680A|2007-11-05|Amorphous atorvastatin calcium
    WO2008153762A2|2008-12-18|S-nitrosothiol formulations and storage systems
    EP1986608B1|2012-11-21|Pharmaceutical composition comprising amorphous atorvastatin
    WO2019004452A1|2019-01-03|Pharmaceutical composition
    JP2006045218A|2006-02-16|Medicinal composition for oral administration
    CZ15276U1|2005-03-29|Stabilized atorvastatin-containing pharmaceutical preparation
    CZ296181B6|2006-01-11|Stabilization method of pharmaceutically active solid substance atorvastatin
    同族专利:
    公开号 | 公开日
    CN1703215A|2005-11-30|
    RU2358727C2|2009-06-20|
    ME00514B|2011-10-10|
    AU2003280361B2|2009-02-26|
    UA85544C2|2009-02-10|
    SI21302A|2004-04-30|
    TWI320709B|2010-02-21|
    EP1608362A1|2005-12-28|
    DE60312049D1|2007-04-05|
    CZ17610U1|2007-06-18|
    US20090012150A1|2009-01-08|
    FIU20070036U0|2007-01-26|
    DK1608362T3|2007-05-14|
    AT354362T|2007-03-15|
    DE60312049T2|2007-10-04|
    RS51819B|2011-12-31|
    AR041588A1|2005-05-26|
    AT10424U1|2009-03-15|
    CN100372529C|2008-03-05|
    RS20050273A|2007-06-04|
    SK50062007U1|2009-03-05|
    DK200700025U4|2008-03-14|
    SK5233Y1|2009-09-07|
    RU2005114485A|2006-01-27|
    US20040077708A1|2004-04-22|
    EP1608362B1|2007-02-21|
    AU2003280361A1|2004-05-04|
    ES2285205T3|2007-11-16|
    SI1608362T1|2007-12-31|
    DE20321455U1|2007-05-24|
    WO2004032920A1|2004-04-22|
    PT1608362E|2007-05-31|
    TW200501947A|2005-01-16|
    FI7617U1|2007-09-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR2194418B2|1971-08-02|1977-01-28|Sada Pietro|
    DE2625164A1|1976-06-04|1977-12-15|Goedecke Ag|Stabilising liq. and semisolid pharmaceutical and cosmetic prepns. - by replacing dissolved oxygen with inert gas e.g. nitrogen|
    US5298627A|1993-03-03|1994-03-29|Warner-Lambert Company|Process for trans-6-[2-alkyl]pyran-2-one inhibitors of cholesterol synthesis|
    DE69506122D1|1994-09-30|1998-12-24|Becton Dickinson Co|METHOD FOR THE PRODUCTION AND PACKAGING OF IONTOPHORETIC PLASTERS AND THEIR LETTERS TO IMPROVE STABILITY AND STORAGE STABILITY|
    GB9425783D0|1994-12-21|1995-02-22|Ethical Pharma Ltd|Packaging of patches|
    HRP960313B1|1995-07-17|2002-08-31|Warner Lambert Co|Form iii crystalline -2- -beta-delta-hydroxy-5- -3-phenyl-4- carbonyl -1h-pyrrole-1-heptanoic acid calcium salt |
    US6087511A|1996-07-16|2000-07-11|Warner-Lambert Company|Process for the production of amorphous [R-]-2--β,δ-dihydroxy-5--3-phenyl-4-[carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt |
    SG125044A1|1996-10-14|2006-09-29|Mitsubishi Gas Chemical Co|Oxygen absorption composition|
    US6155454A|1997-05-03|2000-12-05|Donald C. George|Pill dispenser employing a sealed pill carrier and integrated dispensing plungers|
    US6407278B2|1998-11-16|2002-06-18|Medimmune Oncology, Inc.|Stable amorphous amifostine compositions and methods for the preparation and use of the same|
    US6375956B1|1999-07-22|2002-04-23|Drugtech Corporation|Strip pack|
    DE60041281D1|2000-06-09|2009-02-12|Lek Pharmaceuticals|STABILIZED MEDICAMENT AND DRUG PREPARATION|
    US6293393B1|2000-07-18|2001-09-25|Sdk Co., Inc.|Apparatus and methods for packaging and distributing combinations of foods and beverages|
    SI20848A|2001-03-14|2002-10-31|Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.|Pharmaceutical formulation containing atorvastatin calcium|
    EP1241110A1|2001-03-16|2002-09-18|Pfizer Products Inc.|Dispensing unit for oxygen-sensitive drugs|SI20109A|1998-12-16|2000-06-30|LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d.|Stable pharmaceutical formulation|
    US7411075B1|2000-11-16|2008-08-12|Teva Pharmaceutical Industries Ltd.|Polymorphic form of atorvastatin calcium|
    US7501450B2|2000-11-30|2009-03-10|Teva Pharaceutical Industries Ltd.|Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms|
    IL156055D0|2000-11-30|2003-12-23|Teva Pharma|Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms|
    WO2003057593A1|2001-12-21|2003-07-17|Nektar Therapeutics|Capsule package with moisture barrier|
    RS20060081A|2003-08-05|2008-06-05|Zentiva A.S.,|Methods for the stabilization of atorvastatin|
    DK1727795T3|2004-03-17|2012-04-16|Ranbaxy Lab Ltd|PROCEDURE FOR THE PREPARATION OF ATORVASTATIN CALCIUM IN AMORF FORM|
    AU2005263550C1|2004-07-16|2013-01-17|Lek Pharmaceuticals D.D.|Oxidative degradation products of atorvastatin calcium|
    CA2582449A1|2004-09-30|2006-04-13|Dr. Reddy's Laboratories Ltd.|Amorphous atorvastatin calcium|
    JP2008521878A|2004-12-02|2008-06-26|ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー|Pharmaceutical composition of amorphous atorvastatin and process for its production|
    TWI318571B|2005-06-10|2009-12-21|Lilly Co Eli|Formulation of a thienopyridine platelet aggregation inhibitor|
    US20090216029A1|2005-09-16|2009-08-27|Yatendra Kumar|Process for the production of atorvastatin calcium in amorphous form|
    CA2547216A1|2005-09-21|2007-03-21|Renuka D. Reddy|Process for annealing amorphous atorvastatin|
    US20090247603A1|2005-12-23|2009-10-01|Orbus Pharma, Inc.|Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor|
    EP1810667A1|2006-01-20|2007-07-25|KRKA, tovarna zdravil, d.d., Novo mesto|Pharmaceutical composition comprising amorphous atorvastatin|
    GB2450117A|2007-06-13|2008-12-17|Reckitt Benckiser Healthcare|A water- and oxygen-occlusive blister tablet pack|
    JP2010534644A|2007-07-27|2010-11-11|シプラ・リミテッド|Pharmaceutical composition and method for producing the same|
    US20090071855A1|2007-09-14|2009-03-19|Bahuguna Sumit|Packaging for amorphous statins and compositions thereof|
    EP2127628A1|2008-05-27|2009-12-02|Ranbaxy Laboratories Limited|Unit dose pack|
    US20120244220A1|2009-12-25|2012-09-27|Sawai Pharmaceutical Co., Ltd.|Atrovastatin-containing coated preparation|
    RU2014124118A|2011-11-15|2015-12-27|Др. Редди'С Лабораторис Лтд.|PHARMACEUTICALS, INCLUDING ATORVASTATIN AND GLIMEPIRIDE|
    CN102525942A|2012-01-05|2012-07-04|金陵药业股份有限公司|Atorvastatin calcium enteric-coated pellet and preparation method thereof|
    EP3265078A1|2015-02-03|2018-01-10|Kadmon Pharmaceuticals, LLC|Stable trientine formulations|
    US10905113B2|2015-11-12|2021-02-02|Regents Of The University Of Minnesota|Compositions and method for storing liquid biospecimens|
    EP3184103A1|2015-12-21|2017-06-28|Hexal AG|Pharmaceutical composition comprising atorvastatin or a salt thereof|
    法律状态:
    2013-10-25| UUP| Utility model expired|Expiry date: 20131010 |
    优先权:
    申请号 | 申请日 | 专利标题
    SI200200244A|SI21302A|2002-10-11|2002-10-11|Stabilized pharmaceutical product with amorphous active ingredient|
    [返回顶部]